Active-ingredient Dossier
Lenalidomide
Active-ingredient Dossier for Lenalidomide (immunomodulatory agent). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.
- Brand: LENALIDE
- Brand: LENALIDOMIDE DR.REDDY'S
- Brand: REVLIMID
- Brand: LENALIDOMIDE SANDOZ
- Brand: LENALIDOMIDE VIATRIS
- Brand: LENALEX
- Therapeutic area: Oncology
- Therapeutic area: Haematology
What is
Lenalidomide Lenalidomide is an immunomodulatory agent.
Australian brands containing
Lenalidomide — LENALIDE — LENALIDOMIDE DR.REDDY'S — REVLIMID — LENALIDOMIDE SANDOZ — LENALIDOMIDE VIATRIS
Therapeutic areas
Lenalidomide is registered in oncology, with 14 brands containing this ingredient on the ARTG.
Sponsor landscape
Eight sponsors market lenalidomide in Australia: Dr Reddys Laboratories, Juno Pharmaceuticals, Cipla, Sun Pharma, Arrotex Pharmaceuticals, and Sandoz.
PBS and regulatory activity
Three brands containing lenalidomide have PBS-listed items, with the latest PBS schedule date of 1 May 2026. In the 2023–24 fiscal year, government expenditure on lenalidomide was $84,505,510.11 across 47,638 prescriptions. The latest PBAC outcome was recorded on 1 November 2023, and the latest AusPAR was published on 7 March 2016.